Jaskula-Sztul R - Search Results

1

Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method.

Pinchot SN, Jaskula-Sztul R, Ning L, Peters NR, Cook MR, Kunnimalaiyaan M, Chen H. Pinchot SN, et al. Cancer. 2011 Apr 1;117(7):1386-98. doi: 10.1002/cncr.25652. Epub 2010 Nov 8. Cancer. 2011. PMID: 21425138 Free PMC article.

2

Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells.

Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, Ning L, Haymart M, Kunnimalaiyaan M, Chen H. Greenblatt DY, et al. Oncologist. 2007 Aug;12(8):942-51. doi: 10.1634/theoncologist.12-8-942. Oncologist. 2007. PMID: 17766653 Free article.

3

Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells.

Greenblatt DY, Cayo M, Ning L, Jaskula-Sztul R, Haymart M, Kunnimalaiyaan M, Chen H. Greenblatt DY, et al. J Gastrointest Surg. 2007 Nov;11(11):1515-20; discussion 1520. doi: 10.1007/s11605-007-0249-1. Epub 2007 Sep 15. J Gastrointest Surg. 2007. PMID: 17874277

4

Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma.

Ning L, Jaskula-Sztul R, Kunnimalaiyaan M, Chen H. Ning L, et al. Ann Surg Oncol. 2008 Sep;15(9):2600-5. doi: 10.1245/s10434-008-0006-z. Epub 2008 Jun 18. Ann Surg Oncol. 2008. PMID: 18563491 Free PMC article.

5

Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth.

Cook MR, Pinchot SN, Jaskula-Sztul R, Luo J, Kunnimalaiyaan M, Chen H. Cook MR, et al. Mol Cancer Ther. 2010 Feb;9(2):429-37. doi: 10.1158/1535-7163.MCT-09-0718. Epub 2010 Jan 26. Mol Cancer Ther. 2010. PMID: 20103603 Free PMC article.

6

Expression of the active Notch1 decreases MTC tumor growth in vivo.

Jaskula-Sztul R, Pisarnturakit P, Landowski M, Chen H, Kunnimalaiyaan M. Jaskula-Sztul R, et al. J Surg Res. 2011 Nov;171(1):23-7. doi: 10.1016/j.jss.2011.03.035. Epub 2011 Apr 13. J Surg Res. 2011. PMID: 21571316 Free PMC article.

7

A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma.

Mohammed TA, Holen KD, Jaskula-Sztul R, Mulkerin D, Lubner SJ, Schelman WR, Eickhoff J, Chen H, Loconte NK. Mohammed TA, et al. Oncologist. 2011;16(6):835-43. doi: 10.1634/theoncologist.2011-0031. Epub 2011 May 31. Oncologist. 2011. PMID: 21632454 Free PMC article. Clinical Trial.

8

Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch.

Carter Y, Jaskula-Sztul R, Chen H, Mazeh H. Carter Y, et al. Neuroendocrinology. 2013;97(1):57-66. doi: 10.1159/000335136. Epub 2012 Feb 14. Neuroendocrinology. 2013. PMID: 22343668 Free PMC article. Review.

9

Chrysin activates Notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma in vitro and in vivo.

Yu XM, Phan T, Patel PN, Jaskula-Sztul R, Chen H. Yu XM, et al. Cancer. 2013 Feb 15;119(4):774-81. doi: 10.1002/cncr.27742. Epub 2012 Sep 18. Cancer. 2013. PMID: 22991264 Free PMC article.

10

Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy.

Xiao Y, Jaskula-Sztul R, Javadi A, Xu W, Eide J, Dammalapati A, Kunnimalaiyaan M, Chen H, Gong S. Xiao Y, et al. Nanoscale. 2012 Nov 21;4(22):7185-93. doi: 10.1039/c2nr31853a. Nanoscale. 2012. PMID: 23070403 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

63 results

Search Page

Filters